AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 03:31:14 2024-04-25 am EDT			5-day change	1st Jan Change
11,961 ^GBX	+5.36%		+9.55%	+12.79%

09:24am	FTSE 100 hits record high on big mining M&A, earnings push	RE
08:58am	Miner Anglo American reviews takeover bid from rival BHP	AN

ASTRAZENECA : Goldman Sachs reiterates its Sell rating

June 04, 2021 at 07:35 am EDT

Keyur Parekh from Goldman Sachs retains his negative opinion on the stock with a Sell rating. The target price is unchanged and still at GBX 6800.

Latest news about AstraZeneca PLC

FTSE 100 hits record high on big mining M&A, earnings push	03:24am	RE
Miner Anglo American reviews takeover bid from rival BHP	02:58am	AN
Miner Anglo American eyes rival BHP takeover	02:44am	AN
AstraZeneca Earnings, Sales Rise, Beat Forecasts	02:37am	DJ
AstraZeneca Reports Growth in Q1 Attributable Profit, Total Revenue	02:30am	MT
Earnings Flash (AZN.L) ASTRAZENECA Posts Q1 EPS $1.40	02:13am	MT
AstraZeneca beats first-quarter revenue, profit estimates	02:06am	RE
Stocks called down ahead of US GDP data	01:50am	AN
Sanofi Q1 profit slips on generic competition, forex effects	01:30am	RE
MORNING BID EUROPE-Gearing up for the tech roller-coaster ride	12:31am	RE
EMEA Morning Briefing : Shares Seen Lower; Earnings, U.S. GDP Data in Focus	12:16am	DJ
No record close for FTSE 100; mixed trade in US	Apr. 24	AN
No record close for FTSE 100; mixed trade in US	Apr. 24	AN
Angle plc to Develop New Cancer Assay in Deal with AstraZeneca	Apr. 24	MT
ASTRAZENECA : Bernstein reiterates its Buy rating	Apr. 24	ZD
Angle shares jump on supplier agreement with with AstraZeneca	Apr. 24	AN
AIM WINNERS & LOSERS: Filtronic jumps as lifts outlook	Apr. 24	AN
Angle PLC Announces New Commercial Agreement with AstraZeneca PLC	Apr. 24	CI
AstraZeneca's Voydeya Approved as Add-on Therapy in Europe for Blood Disorder	Apr. 23	MT
ASTRAZENECA : JP Morgan reaffirms its Buy rating	Apr. 23	ZD
AstraZeneca: Voydeya approved in the EU as a treatment for HPN	Apr. 23	CF
AstraZeneca Obtains EU Approval for Voydeya as Add-on Treatment for Rare Blood Disease	Apr. 23	MT
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	Apr. 22	MT
AstraZeneca: presents new data at ECCMID	Apr. 17	CF
The market is pinning its hopes on earnings reports	Apr. 17

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

02:00am - Q1 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : AstraZeneca should not be overlooked for long

April 03, 2024 at 10:26 am EDT

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

141.1 USD

Average target price

161.4 USD

Spread / Average Target

+14.36%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+12.79%	219B
ELI LILLY AND COMPANY	+25.61%	660B
NOVO NORDISK A/S	+23.15%	562B
JOHNSON & JOHNSON	-5.24%	358B
MERCK & CO., INC.	+16.49%	322B
ABBVIE INC.	+8.28%	297B
ROCHE HOLDING AG	-9.20%	196B
NOVARTIS AG	+6.94%	199B
PFIZER, INC.	-8.75%	149B
AMGEN INC.	-5.21%	146B

Other Pharmaceuticals

AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

ASTRAZENECA : Goldman Sachs reiterates its Sell rating

Latest news about AstraZeneca PLC

Chart AstraZeneca PLC

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for AstraZeneca PLC

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals